IsoTis Reports Interim Results of Vote for Integra Merger

    IRVINE, CA, Oct. 16 /CNW/ - IsoTis, Inc. (NASDAQ:   ISOT) ("IsoTis"), an
orthobiologics company, today announced the interim tabulation results of the
special stockholders meeting held on October 11, 2007 and adjourned to October
23, 2007.
    Prior to October 11, 2007, approximately 2,555,000 shares, 36 percent of
the shares entitled to vote, voted for the merger with Integra LifeSciences
Holdings Corporation (NASDAQ:   IART) ("Integra") pursuant to an agreement and
plan of merger dated as of August 6, 2007.
    The votes "for" the merger represented 93% percent of the total number of
approximately 2,753,000 votes cast prior to October 11, 2007. As announced on
October 12, 2007, the number of shares represented at the meeting was
insufficient to establish the quorum of 3,549,615 shares necessary to approve
the proposed merger. The special stockholders meeting has been adjourned to
October 23, 2007 at 7.30 a.m. Pacific time. It will be held at the offices of
Latham & Watkins LLP, 650 Town Center Drive, Suite 2000, Costa Mesa CA.
    The vast majority of IsoTis' stockholder base resides outside the United
States of America and includes thousands of Swiss and Dutch private
individuals. Based on the results now available, many of these shares have not
been voted.
    The adjournment of the meeting will provide these and other IsoTis
stockholders additional time to vote their shares. It will also allow their
Swiss and Dutch banks and brokers to be more effective informing these
stockholders about the transaction, and to take and pass on their votes to the
US custodian banks. Approximately 999,000 additional shares voting in favor of
the proposed transaction are necessary to approve the Integra acquisition.
    IsoTis also announced that it will host two conference calls on October
17, where investors can ask questions about the special stockholders meeting
in German, French, Dutch or English:

    Conference call details
    Date: October 17, 2007

    German/French/English operator
    Time: 16:30-17:30 CET
    Dial In: 00-41-(0)91-610-5609

    Dutch/English operator
    Time: 17:30-18:30 CET
    Dial In: 00-800-4546-4748

    The IsoTis Board of Directors continues to believe unanimously that the
interests of IsoTis' stockholders are best served by the acquisition by
Integra, and that there are no feasible alternatives for the company and the
stockholders. If IsoTis is unable to obtain the vote necessary to approve the
proposed transaction, the company believes it will have to seek bankruptcy

    About IsoTis

    IsoTis is an orthobiologics company that develops, manufactures and
markets proprietary products for the treatment of musculoskeletal diseases and
disorders. IsoTis' current orthobiologics products are bone graft substitutes
that promote the regeneration of bone and are used to repair natural,
trauma-related and surgically-created defects common in orthopedic procedures,
including spinal fusions. IsoTis' current commercial business is highlighted
by its Accell line of products, which the company believes represents the next
generation in bone graft substitution.
    On August 7, 2007 Integra and IsoTis announced that they have reached a
definitive agreement to create a global orthobiologics leader. The combination
would create a comprehensive orthobiologics portfolio, one of the largest
sales organizations focused on orthobiologics in the US, and multiple
cross-selling opportunities. The transaction is subject to approval of IsoTis'
stockholders, as well as other closing conditions and approvals. Upon closing,
IsoTis will become a wholly-owned subsidiary of Integra and Integra will be
one of the largest companies in the world focused on advanced technology in

    Forward-Looking Statements

    Certain statements in this press release are "forward-looking statements"
within the meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, including those that refer to management's plans and expectations
for, among other things, future operations, strategies, prospects, performance
and financial condition and IsoTis' proposed acquisition by Integra. Words
such as "strategy," "expects," "plans," "anticipates," "believes," "may,"
"will," "might," "could," "would," "continues," "estimates," "intends,"
"pursues," "projects," "goals," "targets" or the negative or other variations
thereof and other words of similar meaning are intended to identify such
forward-looking statements. One can also identify them by the fact that they
do not relate strictly to historical or current facts. Such statements are
based on the current expectations and projections of the management of IsoTis
only. Undue reliance should not be placed on these statements because, by
their nature, they are subject to known and unknown risks and can be affected
by factors that are beyond the control of IsoTis. Actual results could differ
materially from current expectations and projections. Any forward-looking
statements are made pursuant to the Private Securities Litigation Reform Act
of 1995 and, as such, speak only as of the date made. IsoTis undertakes no
obligation to publicly update any forward-looking statements, whether as a
result of new information, future events or otherwise.
    A special stockholder meeting was held on October 11, 2007 to obtain
stockholder approval of the proposed transaction. This meeting has been
adjourned to October 23, 2007. IsoTis has filed with the Securities and
Exchange Commission and distributed to its stockholders a definitive proxy
statement and other relevant documents in connection with the special
stockholder meeting for the proposed transaction. IsoTis stockholders are
urged to read the definitive proxy statement and other relevant materials
because they contain important information about IsoTis, Integra and the
proposed transaction. Investors may obtain a free copy of these materials and
other documents filed by IsoTis with the Securities and Exchange Commission at
the SEC's website at, at IsoTis' website at or by sending a written request to IsoTis at 2 Goodyear,
Irvine, California 92618, Attention: Chief Financial Officer.
    IsoTis and its directors, executive officers and certain other members of
management and employees may be deemed to be participants in soliciting
proxies from its stockholders in favor of the proposed merger. Information
regarding the persons who may, under the rules of the SEC, be considered to be
participants in the solicitation of IsoTis' stockholders in connection with
the proposed transaction is set forth in IsoTis' definitive proxy statement
for its special meeting. Additional information regarding these individuals
and any interest they have in the proposed transaction is set forth in the
definitive proxy statement on file with the SEC.

For further information:

For further information: Rob Morocco, CFO, (949) 855-7155,; Hans Herklots, Director IR, (949) 855-7195 or

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890